I
nterleukin-22 (IL-22) plays a dual role in autoimmune and inflammatory diseases (for reviews, see references 1 and 2). It is produced by conventional lymphocytes and by lymphoid cells displaying "innate-like" functions (3) (4) (5) (6) (7) (8) (9) (10) (11) . Among the later group are certain subsets of retinoic acid receptor-related orphan receptor-␥t (ROR␥t)-positive ␣␤ and ␥␦ T lymphocytes and innate lymphoid cells (termed as ILC3) (4, (7) (8) (9) (10) (11) (12) . IL-22 solely acts on nonhematopoietic cells, including hepatocytes and epithelial cells, to exert both proinflammatory and tissue-protective properties depending on the context and the tissue in which it is expressed (2, (13) (14) (15) (16) . In experimental noninfectious systems, IL-22 exerts a potent protective effect on hepatocytes and epithelial cells at barrier surfaces, particularly in the intestine and in the thymus (17) (18) (19) (20) (21) . IL-22 is also a key factor controlling mucosal immunity and the dissemination of commensal bacteria from the intestinal tract (22) . In the lungs, IL-22 protects against experimental lung fibrosis (23) and ventilator-induced lung injury (24) . IL-22 also limits Th2-mediated airway inflammation and tissue damage during asthma (25) (26) (27) . On the other hand, uncontrolled IL-22 production favors dermal inflammation and acanthosis, bleomycin-induced airway inflammation, collagen-induced arthritis, and lipopolysaccharide shock, in part by enhancing tissue inflammation in concert with inflammatory factors such as tumor necrosis factor alpha (TNF-␣) and IL-17 (4, (28) (29) (30) (31) .
During infection, IL-22 production by innate cells or effector conventional T cells plays a dual role depending on the pathogen and the tissue. The early production of IL-22 by innate immune cells is crucial for host protective immunity to extracellular bacteria, including Klebsiella pneumoniae in the lung and Citrobacter rodentium in the intestine (32, 33) . On the other hand, IL-22 has no substantial role in host defense against Staphylococcus aureus, Mycobacterium tuberculosis, M. avium, Listeria monocytogenes, Candida albicans, or Schistosoma mansoni (34) (35) (36) (37) . Of importance, IL-22 can provide protective innate immunity when the adaptive immune system is impaired. This redundant function has been described during infection with C. albicans and Eimeria falciformis (38) (39) (40) . Finally, a deleterious role for IL-22 on intestinal inflammation was reported after oral infection with Toxoplasma gondii (37, 41) .
The potential role of IL-22 during viral infection has recently been addressed. IL-22 might participate in resistance to human immunodeficiency virus infection in subjects who do not sero-convert despite multiple exposures to the virus (42, 43) . Recent data also indicated that reduced IL-22 production in the gut mucosa is important in human immunodeficiency virus mucosal immunopathogenesis (44) . On the other hand, although hepatic IL-22 expression is upregulated in viral hepatitis, IL-22 lacks direct antiviral activity against hepatitis B and C viruses (45, 46) . Of interest, IL-22 aggravates tissue inflammation during experimental hepatitis B virus infection (47) and West Nile virus encephalitis (48) . The potential role of IL-22 in antiviral host defense and virus-associated inflammation has recently been studied during experimental influenza A virus (IAV) infection. Using neutralizing antibodies (Abs), Guo et al. (49) initially showed that IL-22 has little role during acute H1N1 IAV infection, as assessed by IAVassociated morbidity and mortality. In parallel, Monticelli et al. recently reported that during mild, resolving H1N1 IAV infection, neutralization of IL-22 had no impact on the morbidity, on the decreased lung function and on respiratory tissue remodeling (50) . In contrast, based on in vitro assays and using IL-22-deficient mice, we suggested that during the early phase of H3N2 IAV infection (day 4), IL-22 protects bronchial epithelial cells against damages caused by IAV (51) . In this report, invariant natural killer T (iNKT) cells were characterized as cellular sources of IL-22. In line with our observation, IL-22 was next reported to participate in airway epithelial regeneration during the resolution phase of H1N1 IAV infection (days 7 to 18) (52) . Surprisingly, enough, in this later report, ROR␥t-negative conventional NK cells were shown to be the main producers of IL-22 (52) . The aims of the present study were to characterize the cellular sources of IL-22 during the early phase of H3N2 IAV infection and to study its potential role on the development of viral pathogenesis and host responses during infection. To this end, an acute lethal model of IAV infection, where animals succumbed to pneumonia, and a model of infection where animals ultimately resolved inflammation, were used. Since bacterial superinfections can occur after primary IAV infection, a phenomenon accounting for a high rate of morbidity and mortality worldwide (53-60), we also examined the role of endogenous IL-22 in secondary bacterial infection following influenza virus infection. We show that IL-22 is produced by several subsets of lung ROR␥t-positive, but not ROR␥t-negative (including NK cells), cells early after infection. In both lethal and sublethal conditions, IL-22 plays no role in the control of virus replication and in the promotion of the virus-specific CD8 ϩ T cell response. Of interest, during sublethal influenza, but not lethal influenza, IL-22 plays a protective function against respiratory tissue damages caused by IAV, a phenomenon associated with a higher resistance to secondary bacterial infections.
MATERIALS AND METHODS
Virus, bacteria, and mice. The highly pathogenic human-origin H3N2 IAV strain Scotland/20/74 and S. pneumoniae serotype 1 clinical isolate E1586 sequence type ST304 have been described (61) (62) (63) (64) . Interleukin-22 Ϫ/Ϫ mice, backcrossed at least 10 times in C57BL/6 (65), as well as WT littermate controls, were bred in the Ludwig Institute (Brussels, Belgium). ROR␥t-green fluorescent protein (GFP) mice were described earlier (66, 67 Abs and reagents. Monoclonal Abs against mouse TCR␤ (allophycocyanin [APC] and V450 conjugated), TCR␥␦ (PerCP-Cy5.5 conjugated), CD45 (eFluor605NC, Pacific Blue, or APC-H7 conjugated), NKp46 (phycoerythrin [PE] conjugated), CD127 (PE-Cy7 conjugated), CD90.2 (Alexa Fluor 700 conjugated), streptavidin (Alexa Fluor 700 or PE conjugated), and CD4 (APC-H7-conjugated) were purchased from BD Biosciences (Le Pont de Claix, France). The biotin mouse lineage panel was from BD Biosciences. APC-conjugated and PE-conjugated phosphate-buffered saline (PBS)-57-loaded CD1d tetramers were, respectively, obtained from ProImmune (Oxford, United Kingdom) and the NIAID Tetramer Facility (Emory University, Atlanta, GA). The monoclonal Ab against mouse IL-22 (clone 3F11) was kindly provided by W. Ouyang (Genentech, San Francisco, CA). Recombinant IL-22 was produced as described previously (68) .
IAV infection and assessment of gene expression by quantitative RT-PCR. Mice were anesthetized and administered intranasally (i.n.) with 50 l of PBS containing different dose (50 or 600 PFU) of virus (Scotland/20/74, H3N2). Total RNA from whole lungs or from cells recovered from the bronchoalveolar lavages (BAL) of mock-treated or IAVinfected mice was extracted and cDNA was synthesized by classical procedures. Quantitative reverse transcription-PCR (RT-PCR) was carried out as described previously (51) . Primers specific for the gapdh, Ifng, Il17a, mx1, Ifnb, Il22, and IAV M2 genes have been described (51) . In addition, the following primers were used: Il22bp, 5=-ACTCTGCCTGGACCAGG ACA-3= and 5=-GAGAAGCACCCGCAAAGATG; Il23p19, 5=-AATCTCT GCATGCTAGCCTGG-3= and 5=-GATTCATATGTCCCGCTGGTG-3=; Il1b, 5=-TCCCCAACTGGTACATCAGCA-3= and 5=-ACACGGATTCCA TGGTGAAGTC-3=; Rorgt, 5=-TGAAAGCAGGAGCAATGGAAGT-3= and 5=-ACAGCTCCACACCACCGTATTT-3=; Ahr, 5=-ATCGACATAAC GGACGAAATCC-3= and 5=-TTAGGTGCTGAGTCACAGGCTG-3=; Il6, 5=-AGCCTCCGACTTGTGAAGTG-3= and 5=-CTGATGCTGGTGACA ACCAC-3=; Il17f, 5=-TGTCCTCCCCTGGAGGATAAC-3= and 5=-GAAC TGGAGCGGTTCTGGAA-3=; Il21, 5=-AAACTCAAGCCATCAAACCCT G-3= and 5=-TGTTTCTTTCCTCCCCTCCTG-3=; and Tnfa, 5=-CATCTT CTCAAAATTCGAGTGACAA-3= and 5=-TGGGAGTAGACAAGGTAC AACCC-3=. ⌬C T values were obtained by deducting the raw cycle threshold (C T values) obtained for gapdh mRNA, the internal standard, from the C T values obtained for investigated genes.
Analysis of IL-22 transcript levels in ROR␥t-positive cells during IAV infection. ROR␥t-GFP mice were infected, or not, with IAV, and lung MNCs were prepared 60 h postinfection (p.i. , n ϭ 12 to 15. Significant differences were determined using a one-way analysis of variance, followed by a Bonferroni post test (*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001).
Analysis of IL-22-producing cells. Analysis of IL-22-producing cells was assessed 2 days post-IAV infection. As a possible control, lung MNCs were cultured at 10 7 cells/ml in complete medium containing 10 ng of recombinant mouse IL-1␤/ml and IL-23 plus 10 g of brefeldin A (SigmaAldrich, Steinheim, Germany)/ml at 37°C for 4 h. After activation, cells were washed and stained with Live/Dead fixable dead cell stain kit (Life Technologies, Carlsbad, CA) in PBS for 30 min. The cells were washed and incubated with appropriate dilutions of eFluor605NC-conjugated CD45, PE-conjugated PBS-57-loaded CD1d tetramer, V450-conjugated anti-TCR␤ Ab, and PerCP-Cy5.5-conjugated anti-TCR␥␦ Ab for 30 min in PBS containing 2% fetal calf serum (FCS). Cells were washed and fixed using IC fixation buffer (eBioscience, CliniSciences, Montrouge, France). Fixed cells were then permeabilized in permeabilization buffer (eBioscience), according to the manufacturer's instructions. Cells were stained with APC-conjugated MAb against IL-22 or control mouse IgG2a MAb and analyzed on a LSR Fortessa (BD Biosciences). To analyze the proportions of innate lymphoid cells (ILCs) in ROR␥t-positive TCR␣␤ Ϫ TCR␥␦ Ϫ cells, lung MNCs from ROR␥t-GFP mice were labeled with appropriate dilutions of APC-H7-conjugated anti-CD45, Percp-Cy5.5-conjugated anti-TCR␥␦, V450-conjugated anti-TCR␤, a biotin lineage-specific Ab cocktail (TER119, CD11b, Gr1, B220, CD3, CD11c, and NK1.1) plus a PE-conjugated streptavidin, PE-Cy7-conjugated anti-CD127, and Alexa Fluor 700-conjugated CD90.2. Cells were analyzed on a LSR Fortessa.
Assessment of the mortality rate and of the pathology. After IAV infection (600 or 50 PFU), mice were monitored daily for illness and mortality for a period of 17 days. Disease was assessed by measuring lung inflammation, viral load in the lungs, and lethality. Mice found to be moribund were euthanized and considered to have died on that day. Mice were also sacrificed at day 7 p.i. to recover the whole lung and the BALs. For histopathologic examination, lungs were fixed by inflation and immersion in PBS-3.2% paraformaldehyde and then embedded in paraffin.
To evaluate airway inflammation, we subjected fixed lung slices (5-m sections) to hematoxylin and eosin (H&E) staining. Evaluators who were blinded to genotype scored lung sections (0 [none] to 3 [extreme]) according to criteria described by Paget et al. (69) .
Analysis of the viral load and of the IAV-specific CD8 ؉ T cell response. Lungs were homogenized and virus titers determined using a standard plaque assay on Mardin-Darby canine kidney cells. Ifnb and mx1 mRNA expression levels were determined by quantitative RT-PCR as described previously (69) . The number of IAV-specific CD8 ϩ T cells was determined as reported (69) . For this, cells specific for an immunodominant D b -restricted CD8 ϩ T epitope derived from the viral polymerase 2 protein (PA 224-233 ) (70) were analyzed. Briefly, lung MNCs were incubated with appropriate dilutions of APC-conjugated anti-CD19, fluorescein isothiocyanate-labeled anti-CD8 and PE-conjugated Pro5 major histocompatibility complex pentamer H-2D b SSLENFRAYV. To assess the functionality of virus-specific CD8 ϩ T cells, lung cells and cells isolated from the lung draining (mediastinal) lymph nodes (dLNs) were stimulated with the peptide SSLENFRAYV (10 g/ml), and cytokine production was assessed by enzyme-linked immunosorbent assay (ELISA).
Secondary infection with S. pneumoniae. Mice, infected or not with IAV (50 PFU) 7 days earlier, were i.n. inoculated with 10 4 S. pneumoniae serotype 1. In naive animals, this dose is self-limiting since mice cleared the bacteria within 24 h. In some circumstances, Il22 Ϫ/Ϫ mice received by the i.n. route recombinant IL-22 (5 g/mouse) or vehicle (PBS) just before IAV infection and 2 days p.i. Mice were monitored daily for illness and mortality for a period of 13 days. The number of viable bacteria in the lungs was determined 24 h after S. pneumoniae challenge. This was measured by plating lung homogenates onto blood agar plates (71) . CFU were enumerated 24 h later. A morphology-based differential cell count was conducted on cytospin preparations from the BAL fluid and stained with Diff-Quik solution (Sigma).
Statistical analysis. Results are expressed as the means Ϯ the standard deviations (SD) or Ϯ the standard errors of the mean (SEM). The statistical significance of differences between experimental groups was calculated by a one-way analysis of variance, followed by a Bonferroni posttest (Prism 4 Software; GraphPad, San Diego, CA). The possibility to use these parametric tests was assessed by checking whether the population is Gaussian and the variance is equal (Bartlett's test). Results with a P value of Ͻ0.05 were considered significant (*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001).
RESULTS

IL-22 is produced in the lungs during the early stages of IAV infection.
The kinetics of IL-22 expression during the early phases of IAV infection are ill-defined, although we and others have shown that natural killer (NK) cells and invariant natural killer (iNKT) cells are primary sources of IL-22 2 days after H1N1 or H3N2 IAV infection, respectively (49, 51) . As shown in Fig. 1A (left panels), and relative to mock-treated animals, a higher level of Il22 gene transcript was detected in the lung tissue and alveolar spaces of IAV-infected mice 2 and 4 days p.i. (ϳ10-fold enhancement). An enhanced concentration of IL-22 protein was also detected 2 days, but not 4 days, p.i. (Fig. 1A , right panels), a phenomenon probably due to its rapid consumption. IL-22 activity can be neutralized in vivo by its specific opponent IL-22 binding protein (IL-22BP) (72) . As seen in Fig. 1B , Il22bp messengers were slightly downregulated (ϳ2-fold) at day 2 and 4 p.i. in the lung tissue and the decrease was more important (ϳ20-fold) in the BALs. The ratio of Il22 to Il22bp was ϳ10-fold higher in the BALs compared to the lung tissue and did not significantly differ at days 2 and 4 p.i. Il17a and IL17f transcripts were also found to be upregulated 2 and 4 days p.i. in the BAL cells, but not in pulmonary cells, whereas Il21, another member of the IL-17 family, was not modulated (not shown). Augmented IL-17A protein was also detected at day 2 p.i., but only in the BAL fluids (not shown). IL-23, IL-1␤, IL-6, and TNF-␣ have been described to participate in early IL-22 production in some settings (for reviews, see references 2, 8, and 9). As seen in Fig. 1C, Il23, Il1b , Il6, and Tnfa gene transcripts were strongly upregulated in the BAL cells and in the lungs (data not shown) by 2 and 4 days p.i. Enhanced IL-23, IL-1␤, IL-6, and TNF-␣ protein levels were also evident at these time points (Fig. 1D) . Of note, ROR␥t, and to a lesser extent, aryl hydrocarbon receptor, transcription factors known to be crucial in IL-22 synthesis (2, 8, 9 ), were also upregulated at the transcript level (Fig. 1E) . Collectively, IL-22, as well as factors known to regulate its expression, are produced in the lungs during the early stages of H3N2 IAV infection.
ROR␥t-expressing cells produce enhanced IL-22 transcripts early after IAV infection. We took advantage of ROR␥t-GFP mice to analyze the early source(s) of IL-22 during IAV infection. As seen in Fig. 2A (Fig. 2B) .
The different pulmonary ROR␥t-expressing cell populations were next sorted from mock-treated and IAV-infected animals and analyzed for Il22 gene transcript expression. In agreement with earlier studies (66, 73) , ␣␤ T lymphocytes and ␥␦ T lymphocytes represented the two major populations expressing ROR␥t (Fig. 2C, upper panel) . Invariant NKT cells were discarded from the ␣␤ T lymphocyte pool and were analyzed separately. A fourth population of ROR␥t ϩ cells was also identified. This population, which represents a minor fraction of ROR␥t ϩ cells (ϳ4% of the total pool), contains ϳ70% of Lin Ϫ CD127 ϩ CD90 ϩ CD4 Ϫ cells (data not shown) and was thus termed the ILC3-enriched population (12) . As shown in Fig. 2C (lower panel) , ␣␤ T lymphocytes, ␥␦ T lymphocytes, and iNKT cells, and to a lesser extent the ILC3-enriched population, produced a higher level of Il22 mRNAs in the context of IAV infection.
Analysis of IL-22 protein expression by ROR␥t-expressing cells was next assessed in response to a cocktail of IL-1␤ and IL-23, used here as a positive control. As represented in Fig. 2D , ␣␤ T lymphocytes (mainly CD4 neg ), ␥␦ T lymphocytes, and iNKT cells and, to a lesser extent cells within the ILC-enriched population, produced IL-22. Of note, lung NKp46 ϩ cells failed to express IL-22 in response to IL-1␤ and IL-23 (not shown). In the context of IAV infection, and without ex vivo restimulation, IL-22 protein expression was not evidenced by intracellular staining using fluorescence-activated cell sorting, regardless of the cell population analyzed, the kinetics (60 h and 4 days), and the dose of IAV used (Fig.  2E and data not shown) . The low level of expression and/or the rapid secretion of IL-22 might explain these data.
IL-22 deficiency has no impact on mouse survival, viral clearance, and IAV-specific CD8
؉ T cell response. Severe lung immunopathology strongly contributes to influenza virus-related morbidity and mortality (74) . It is known that IL-22 is a versatile controller of immunopathology (2, 8, 9) . To address its role during influenza, WT and Il22 Ϫ/Ϫ mice were used in survival studies. To rule out potential bias due to genetic background, WT and Il22 Ϫ/Ϫ littermates were used. Upon a lethal dose (600 PFU) of IAV, WT animals demonstrated severe sickness ending in death at day 13 (Fig. 3A) . Although not significant, 10 to 15% of Il22 Ϫ/Ϫ mice survived the infection out to day 18 p.i. In contrast, using a sublethal dose (50 PFU), Il22 Ϫ/Ϫ mice displayed slightly, although not significantly, decreased resistance compared to WT animals.
To determine whether endogenous IL-22 plays a part in viral clearance, the viral load was monitored at day 4 and at day 7 p.i. by plaque assay. Whatever the dose of IAV used, Il22 Ϫ/Ϫ mice controlled virus replication in their lungs with kinetics similar to those for WT animals (Fig. 3B) .
IL-22 has been shown to attenuate antigen (Ag)-induced pulmonary immune responses in some settings (23, (25) (26) (27) . We thus compared the virus-specific CD8 ϩ T cell response in IAV-infected WT and Il22 Ϫ/Ϫ mice in terms of cell number and cytokine production. Whatever the dose of IAV (shown is 50 PFU), the number of lung CD8 ϩ D b PA 224-233 ϩ cells were not different between WT and Il22 Ϫ/Ϫ mice at 4 and 7 days p.i ( Fig. 3C and data not shown). Similarly, upon restimulation with PA 224-233 , the amount of IFN-␥ released by lung cells and by cells from the lung dLNs was identical (Fig. 3D) . Of note, whereas pulmonary and lung dLN cells from IAV-infected mice spontaneously released IL-22 at day 7, IL-22 production was not amplified after IAV peptide restimulation. This indicates the lack of IAV-specific IL-22-producing CD8 ϩ T cells in the context of early IAV, at least in response to the immunodominant peptide used.
Endogenous IL-22 plays a positive role in the control of sublethal, but not lethal, IAV-associated pneumonia. We next addressed the potential role of endogenous IL-22 in the development and/or the control of IAV-associated pulmonary pathogenesis. To do so, lungs from WT and Il22 Ϫ/Ϫ mice infected with a lethal or a sublethal dose of IAV were harvested for histology during the acute-phase response. In conditions where IAV causes acute pneumonia ending by the death of the animals (600 PFU), the lack of IL-22 did not significantly modulate the intensity of the pulmonary inflammation. As shown in Fig. 4A , the cellular infiltration in the lungs, as the well as the alveolitis and bronchiolitis scores, were not significantly different between infected WT and Il22 Ϫ/Ϫ mice. In both infected animal groups, bronchial epithelia were strongly damaged, and this was associated with an impaired epithelial integrity, as measured by the high total protein concentration in the BAL fluid (Fig. 4B) . Values represent the means Ϯ the SD (n ϭ 4 to 6). Significant differences were determined using a one-way analysis of variance, followed by a Bonferroni post test (***, P Ͻ 0.001). 
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In stark contrast, upon a sublethal challenge (50 PFU), a significant enhancement of airway inflammation was noticed in Il22 Ϫ/Ϫ mice relative to WT mice as reflected by the higher histopathology scores in the former group (Fig. 4C) . In Il22 Ϫ/Ϫ mice, alveolitis and bronchiolitis were more pronounced relative to WT littermates ( Fig. 4C and D) . In addition, epithelia surrounding the bronchi from Il22 Ϫ/Ϫ mice were more damaged (Fig. 4D) . Signs of severe injury, characterized by augmented loss of intercellular cohesion and denuded epithelium were observed in Il22 Ϫ/Ϫ animals (scored in Fig. 4C ). This apparent loss of epithelial integrity was associated with a slight enhancement of protein concentration in the BALs (Fig. 4E, left panel) . Of note, the number of red blood (Fig. 4E, right panel) .
IL-22 deficiency leads to an enhanced susceptibility to secondary bacterial infection following influenza virus infection.
Epithelial damages post-influenza virus infection has been proposed to play a part in secondary bacterial infections such as S. pneumoniae (53, 55-57, 59, 60, 75) . We thus investigated the role of endogenous IL-22 in bacterial superinfection following influenza virus infection. Before this, we determined the optimal timing between exposure to the virus and exposure to the bacteria to achieve bacterial superinfection. For this, animals were infected with a sublethal dose of IAV (50 PFU) and were then superinfected with a self-limiting dose of S. pneumoniae (10 4 CFU) at different time points after virus infection. As seen in Fig. 5A , mice challenged with S. pneumoniae 7 days after influenza virus infection had a high number of live bacteria in the lungs, while animals infected after 3 days completely clear the bacteria 24 h after the challenge. Of note, mice infected 2 and 4 weeks after IAV had a lower capacity to control bacterial replication, although the numbers of bacteria in the lungs were much lower relative to those in mice receiving IAV 7 days earlier. Thus, S. pneumoniae was administered 7 days post-IAV infection, the peak of bacterial susceptibility.
At the dose of IAV used (50 PFU), the levels of Il22 mRNA were increased, whereas those of Il22bp were decreased at day 3 and particularly at day 7 p.i. (Fig. 5B) . As a consequence, the ratio of Il22 to Il22bp was higher at day 7 relative to day 3. Of note, this ratio was comparable at 50 and 600 PFU (Fig. 5C ). As expected, preceding IAV infection induced animal death after S. pneumoniae challenge (Fig. 6A, IAVϩSp) . Remarkably, while 50% of IAV-experienced WT mice succumbed following S. pneumoniae infection, almost all coinfected Il22 Ϫ/Ϫ mice died from bacterial infection. This effect was associated with an increased number of viable bacteria in the lung tissue (Fig. 6B) . Of importance, the observed effect was probably not due to a direct antibacterial effect of endogenous IL-22 per se. Indeed, both non-IAV experienced WT and Il22 Ϫ/Ϫ mice survived (Fig. 6A ) and equally cleared bacteria in the lungs after sublethal S. pneumoniae challenge (data not shown). To confirm our findings, Il22 Ϫ/Ϫ mice were administered with recombinant IL-22. Compared to IAV-infected Il22 Ϫ/Ϫ animals treated with vehicle alone, the administration of recombinant IL-22 reduced the number of CFU in the lungs (Fig. 6C) . Thus, the lack of IL-22 worsens the outcome of secondary S. pneumoniae pneumonia. This effect was not associated with a significantly higher IAV burden in the lungs (Fig. 6D) or a differential recruitment of macrophages and neutrophils in the BALs of doubly infected mice, cells known to be crucial in the clearance of S. pneumoniae (76, 77) (Fig. 6E) . Furthermore, the production of factors known to exert antipneumococcal effects, including IFN-␥, IL-17, and the neutrophil-attracting factors CXCL1 and CXCL2, were not different between WT and Il22 Ϫ/Ϫ doubly infected mice (Fig. 6F and not shown) . ICAM-1 plays a role in the control of S. pneumoniae early after infection (78). However, the transcript level of Icam1 remained unchanged between WT and Il22 Ϫ/Ϫ doubly infected mice (data not shown). In the same line, REGIII␥, a known target of IL-22 able to exert an antibacterial effect in the intestine (33) and the lung (34), was not modulated at the transcript level in doubly infected Il22 Ϫ/Ϫ mice, relative to doubly infected WT animals (data not shown). Collectively, endogenous IL-22 limits bacterial superinfection post-influenza virus infection, a phenomenon probably independent from direct enhanced host defense mechanisms.
DISCUSSION
IL-22 participates in host defense against bacteria at mucosal surfaces and plays a part in the maintenance of the barrier integrity, with predominant effects on epithelial cells. However, this cytokine can also serve pathogenic functions in many experimental and clinical settings (1, 2, 13, 29) . In the present study, we show that during nonlethal IAV-induced pathogenesis, IL-22 reduces lung inflammation and maintains pulmonary epithelial integrity, an effect associated with a more controlled secondary bacterial infection following influenza.
During H3N2 infection, and at the transcript level, IL-22 was induced as early as day 2 in the lung tissue and BALs, whereas IL-22BP, the endogenous IL-22 antagonist, was downmodulated. Of note, whatever the dose of IAV, the Il22/Il22bp ratio was enhanced in a similar extent and peaked at day 7 p.i. Along with ROR␥t-positive iNKT cells, other subsets of ROR␥t-positive cells, including ␣␤ T lymphocytes, ␥␦ T lymphocytes, and ILC3, express enhanced Il22 transcript during the early phases of IAV infection. In contrast, ROR␥t-negative cells failed to do so. The absence of IL-22 production by lung NKp46 ϩ cells, either after IL-1␤ plus IL-23 stimulation or in the context of IAV infection, can be explained by the lack of ROR␥t expression by these cells and indicates that among ILC3, lymphoid tissue inducer cells, rather than "NK-like" cells, are a source of IL-22 during early IAV infection. Our data are in contrast to other studies (49, 52) , which reported IL-22 protein production by lung conventional NK cells during the early (day 2) and the later (days 4 and 7) stages of IAV infection. The reasons for this discrepancy may be explained by differences in the virus strains used.
Whatever the dose of IAV, the overall pulmonary viral burdens of Il22 Ϫ/Ϫ mice showed no difference from those of control mice. These data are in line with other studies reporting no direct or indirect antiviral activity of IL-22 (45) (46) (47) (48) (49) . Furthermore, in agreement with a previous finding showing that IL-22 has no impact on Ag-driven lymphocyte priming and expansion (65) , Il22 Ϫ/Ϫ mice had a normal IAV-specific CD8 ϩ T cell response. Thus, IL-22 does not favor or interfere with mechanisms leading to T cell priming in the dLNs. Likewise, IL-22 plays no major role on the synthesis of epithelial-derived chemokines necessary for the recruitment of expanded T cells in the lung compartment.
In response to a highly immunopathogenic IAV dose (600 PFU), Il22 Ϫ/Ϫ mice did not exhibit reduced or enhanced mortality rates. In parallel, compared to WT mice, Il22 Ϫ/Ϫ mice showed no improvement, or conversely dysregulation, of pneumonia. This indicated that during excessive, nonresolving, IAV-associated pneumonia, IL-22 plays no major function. In stark contrast, during sublethal IAV infection where inflammation is less intense and more controlled, endogenous IL-22 reduced lung injury. This did not significantly influence the survival outcome, although a trend toward enhanced mortality was observed in Il22 Ϫ/Ϫ mice. The reason why IL-22 is redundant at a high dose of IAV and beneficial at a sublethal dose is not due to a difference in the levels of IL-22 and IL-22BP expression (at least at the transcript level). A difference in the production of IL-17 and TNF-␣, known to control IL-22 activities (52) . During the early phase of IAV infection, the loss of epithelial integrity plays a major role in the pathology (50, 75) . It leads to the loss of homeostasis and the development of pulmonary inflammation, features found to be enhanced in Il22 Ϫ/Ϫ mice. Epithelial damages are caused by IAV-induced cytopathology and/or the lysis of virus-infected epithelial cells by recruited NK cells, cytotoxic T cells, apoptosis-inducing cytokines, and the activation of death receptors. Our recent data showed that IL-22 protects epithelial cells from cell death after infection with IAV in vitro (51) . In line with this finding, we observed an enhanced level of epithelial damages in infected Il22 Ϫ/Ϫ mice, relative to WT littermates. Although the mechanisms sustaining the protective effect of IL-22 are still unknown, we speculate that its in vivo beneficial effect is due to its role on the maintenance of epithelial integrity. In this setting, IL-22 might play a positive role in the prevention of injury (51) and, as recently demonstrated (52) , in the acceleration of the epithelial repair. Recently, a population of lung ROR␥t-negative ILCs that resembles natural helper cells has been described to play a protective role, through amphiregulin release, on airway epithelia during IAV infection (50) . It is possible that the positive role played by IL-22-producing cells during the early stages of IAV infection complements natural helper cell functions to ensure airway epithelial integrity and lung tissue homeostasis during IAV infection.
It is well documented that IAV infection enhances susceptibility to secondary bacterial infections, leading to increased morbidity and mortality (53) (54) (55) (56) (57) (58) (59) (60) . The mechanisms include alterations of mechanical and immunological defenses. For instance, epithelial cell damages caused by influenza virus improve bacterial adhesion to the mucosa and its subsequent crossing through the lung epithelium. In parallel, impairment of the host innate response is an important feature of bacterial superinfections (53, 55, 59) . In the present study, we report that IAV-experienced Il22 Ϫ/Ϫ mice challenged with S. pneumoniae have decreased survival compared to similarly infected WT animals. We favor the hypothesis that the protective role of IL-22 in bacterial superinfection post-IAV infection is rather due to its positive early effect on lung, including epithelial, injury due to IAV infection rather than to an antibacterial effector mechanisms per se. Indeed, molecular and cellular effectors associated with early innate defense mechanisms against bacteria were not significantly decreased in the absence of IL-22. Thus, by limiting the alteration of the epithelial barrier instigated by IAV, IL-22 might decrease the level of bacterial invasion into the lungs. This hypothesis needs to be confirmed using different IAV subtypes, including H1N1. Since in humans, dysregulation of IL-22 or IL-22 receptor production has been reported in certain pathologies, including psoriasis, Crohn's disease, and allergic diseases (80) , it might be interesting to determine the potential correlation, if any, between susceptibility to bacterial superinfections and IL-22 or IL-22 receptor production in patients. Recent findings suggest that, in combination with antibiotic and antiviral therapies, treatments that protect lung epithelium and/or stimulate lung repair responses could be beneficial in improving survival in patients during influenza virus and bacterial coinfection (50, 75) . Whether IL-22 supplementation in order to improve lung epithelial integrity and to prevent microbial translocation leads to less severe outcome resulting from bacterial complications during influenza virus infection is under intense investigation.
